Brose M.S.Robinson B.Sherman S.I.Krajewska J.CHIA-CHI LINVaisman F.Hoff A.O.Hitre E.Bowles D.W.Hernando J.Faoro L.Banerjee K.Oliver J.W.Keam B.Capdevila J.2022-09-152022-09-1520211470-2045https://www.scopus.com/inward/record.uri?eid=2-s2.0-85111522823&doi=10.1016%2fS1470-2045%2821%2900332-6&partnerID=40&md5=a9984aeb9565b7b3f0e9a9084748a177https://scholars.lib.ntu.edu.tw/handle/123456789/620214[SDGs]SDG3Cabozantinib for radioiodine-refractory differentiated thyroid cancer (COSMIC-311): a randomised, double-blind, placebo-controlled, phase 3 trialjournal article10.1016/S1470-2045(21)00332-6342372502-s2.0-85111522823